Perioperative Stress Management in Outpatient Surgery With L-tyrosine Supplementation (SPOT)

NCT ID: NCT05782829

Last Updated: 2025-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-14

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patient undergoing surgery is exposed to many stressors: diachronic (gesture anticipation), synchronic (intraoperative aggression) and historical (subject's personality). Reducing the level of stress experienced is a factor for improving the quality of the surgical gesture and the simplicity of the follow-up. The previous methods used were intended to reduce the body's reactivity to aggressions through anaesthesia consultation and L-Tyrosine supplementation. Currently with the progression of outpatient surgery and the need for early rehabilitation, L-Tyrosine supplementation is suppressed to improve recovery. Some patients, however, have a high level of stress that may require anxiolysis when the ideal treatment does not exist (ineffective hydroxyzine, benzodiazepines having many side effects). The strategy of this work is to improve the body's ability to respond to stressors, by administering l-tyrosine with no impact on waking or returning home.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

prospective, monocentric, double-blind randomized study
Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

L-Tyrosine

Group Type EXPERIMENTAL

L-tyrosine supplementation

Intervention Type DIETARY_SUPPLEMENT

L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia

Placebo

Group Type PLACEBO_COMPARATOR

Placebo supplementation

Intervention Type DIETARY_SUPPLEMENT

Placebo supplementation before surgery for inguinal hernia under general anaesthesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-tyrosine supplementation

L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia

Intervention Type DIETARY_SUPPLEMENT

Placebo supplementation

Placebo supplementation before surgery for inguinal hernia under general anaesthesia

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Membership of a social security scheme or equivalent
* At least 18 years of age
* Able to express consent
* Indication of unilateral or bilateral inguinal hernia cure
* General anaesthesia proposed and retained for inguinal hernia treatment regardless of surgical technique

Exclusion Criteria

* Surgical indication for another reason or hernial cure associated with another procedure
* Smoking estimated at more than 35 pack-years
* History of psychiatric pathology
* ASA 3 or 4 according to the American Society of Anesthesiologists classification. As a reminder, an ASA 3 class concerns a patient with a severe but not disabling general disease, and an ASA 4 class concerns a patient with a disabling general disease involving the vital prognosis.
* ASA 2 and having at least one of the following pathologies or patients treated with -blockers: insulin-dependent diabetes, high blood pressure, heart rhythm disorder, dysthyroidism, progressive neurological disease, long-term benzodiazepines.
* Starch allergy or intolerance
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nice

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHPG

Monaco, , Monaco

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Monaco

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bertrand PRUNET, PU-PH

Role: CONTACT

+377 97 98 98 19

Nicolas RIJO

Role: CONTACT

+377 97 98 84 45

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bertrand PRUNET, PU-PH

Role: primary

+377 97 98 98 19

Nicolas RIJO

Role: backup

+37797988445

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Beta Caryophyllene & Apnea Performance
NCT07340996 ACTIVE_NOT_RECRUITING NA
Supplement Combination on Stress and Sleep
NCT06889584 ACTIVE_NOT_RECRUITING NA